Monotherapy versus combination therapy for the treatment of chronic hepatitis B

Bibliography

• Iloeje UH, Yang HI, Su J, Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J, Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73
   PubMed Web of Science ®Google Scholar
• Liaw YF, Sung JJ, Chow WC, Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31
   PubMed Web of Science ®Google Scholar
• Yuen MF, Seto WK, Chow DH, Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir Ther 2007;12:1295-303
   PubMed Web of Science ®Google Scholar
• Brunetto MR, Moriconi F, Bonino F, Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49:1141-50
   PubMed Web of Science ®Google Scholar
• Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009;49:S185-S95
   Web of Science ®Google Scholar
• Perrillo RP, Schiff ER, Davis GL, ; The Hepatitis Interventional Therapy Group. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301
   PubMed Web of Science ®Google Scholar
• van Zonneveld M, Honkoop P, Hansen BE, Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004;39:804-10
   PubMed Web of Science ®Google Scholar
• Lau DT, Everhart J, Kleiner DE, Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660-7
   PubMed Web of Science ®Google Scholar
• Rang A, Bruns M, Heise T, Will H. Antiviral activity of interferon-alpha against hepatitis B virus can be studied in non-hepatic cells and Is independent of MxA. J Biol Chem 2002;277:7645-7
   PubMed Web of Science ®Google Scholar
• Lohr HF, Weber W, Schlaak J, Proliferative response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e-minus hepatitis B virus mutants. Hepatology 1995;22:61-8
   PubMed Web of Science ®Google Scholar
• Rico MA, Quiroga JA, Subira D, Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha. Hepatology 2001;33:295-300
   PubMed Web of Science ®Google Scholar
• Flink HJ, Sprengers D, Hansen BE, Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon alpha-2b therapy. Gut 2005;54:1604-9
   PubMed Web of Science ®Google Scholar
• Lau GK, Piratvisuth T, Luo KX, Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95
   PubMed Web of Science ®Google Scholar
• Moucari R, Korevaar A, Lada O, High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009;50:1084-92
   PubMed Web of Science ®Google Scholar
• Cooksley WG, Piratvisuth T, Lee SD, Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305
   PubMed Web of Science ®Google Scholar
• Janssen HL, van Zonneveld M, Senturk H, Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-9
   PubMed Web of Science ®Google Scholar
• Marcellin P, Lau GK, Bonino F, Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17
   PubMed Web of Science ®Google Scholar
• Bonino F, Marcellin P, Lau GK, Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis. B Gut 2007;56:699-705
   PubMed Web of Science ®Google Scholar
• Flink HJ, van Zonneveld M, Hansen BE, Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006;101:297-303
   PubMed Web of Science ®Google Scholar
• Moucari R, Mackiewicz V, Lada O, Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42
   PubMed Web of Science ®Google Scholar
• Datamonitor. Commercial and pipeline insight: hepatitis B. [Report] 2007;1-241
   Google Scholar
• Sharon A, Chu CK. Understanding the molecular basis of HBV drug resistance by molecular modeling. Antiviral Res 2008;80:339-53
   PubMed Web of Science ®Google Scholar
• Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006;26:162-70
   PubMed Web of Science ®Google Scholar
• Libbrecht E, Doutreloigne J, Van De Velde H, Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay. J Clin Microbiol 2007;45:3935-41
   PubMed Web of Science ®Google Scholar
• Degertekin B, Hussain M, Tan J, Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. J Hepatol 2009;50:42-8
   PubMed Web of Science ®Google Scholar
• Gaia S, Marzano A, Smedile A, Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2004;20:281-7
   PubMed Web of Science ®Google Scholar
• Lok AS, Lai CL, Leung N, Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-22
   PubMed Web of Science ®Google Scholar
• Allen MI, Deslauriers M, Andrews CW, Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998;27:1670-7
   PubMed Web of Science ®Google Scholar
• Yang H, Qi X, Sabogal A, Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005;10:625-33
   PubMed Web of Science ®Google Scholar
• HeipertzRA Jr, Miller TG, Kelley CM, In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication. J Virol 2007;81:3068-76
   PubMed Web of Science ®Google Scholar
• Jardi R, Rodriguez-Frias F, Schaper M, Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients. J Viral Hepat 2007;14:835-40
   PubMed Web of Science ®Google Scholar
• Yatsuji H, Noguchi C, Hiraga N, Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother 2006;50:3867-74
   PubMed Web of Science ®Google Scholar
• Villet S, Pichoud C, Billioud G, Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008;48:747-55
   PubMed Web of Science ®Google Scholar
• Gerolami R, Bourliere M, Colson P, Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases. Antivir Ther 2006;11:1103-6
   PubMed Web of Science ®Google Scholar
• Zoulim F, Poynard T, Degos F, A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat 2006;13:278-88
   PubMed Web of Science ®Google Scholar
• Yuen MF, Fong DY, Wong DK, Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 2007;46:1695-703
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung N, Kao JH, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263-83
   PubMed Web of Science ®Google Scholar
• Keeffe EB, Dieterich DT, Han SH, A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6:1315-41
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis 2007;11:965-91
   PubMedGoogle Scholar
• Marcellin P, Chang TT, Lim SG, Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-81
   PubMed Web of Science ®Google Scholar
• Carrouee-Durantel S, Durantel D, Werle-Lapostolle B, Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. Antivir Ther 2008;13:381-8
   PubMed Web of Science ®Google Scholar
• van Bommel F, Wunsche T, Mauss S, Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-5
   PubMed Web of Science ®Google Scholar
• Perrillo R, Schiff E, Yoshida E, Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-34
   PubMed Web of Science ®Google Scholar
• Peters MG, Hann Hw H, Martin P, Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101
   PubMed Web of Science ®Google Scholar
• Fung SK, Andreone P, Han SH, Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005;43:937-43
   PubMed Web of Science ®Google Scholar
• Angus P, Vaughan R, Xiong S, Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-7
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51
   PubMed Web of Science ®Google Scholar
• Pallier C, Rodriguez C, Brillet R, Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology 2009;49:50-9
   PubMed Web of Science ®Google Scholar
• Gaia S, Barbon V, Smedile A, Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol 2008;48:540-7
   PubMed Web of Science ®Google Scholar
• Honkoop P, De Man RA. Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs 2003;12:683-8
   PubMed Web of Science ®Google Scholar
• Langley DR, Walsh AW, Baldick CJ, Inhibition of hepatitis B virus polymerase by entecavir. J Virol 2007;81:3992-4001
   PubMed Web of Science ®Google Scholar
• Lai CL, Shouval D, Lok AS, Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, de Man R, A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10
   PubMed Web of Science ®Google Scholar
• Leung N, Peng CY, Hann HW, Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009;49:72-9
   PubMed Web of Science ®Google Scholar
• Gish RG, Lok AS, Chang TT, Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007;133:1437-44
   PubMed Web of Science ®Google Scholar
• Colonno RJ, Rose R, Baldick CJ, Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006;44:1656-65
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ, Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Levine SM, Rose RE, Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004;48:3498-507
   PubMed Web of Science ®Google Scholar
• Villet S, Ollivet A, Pichoud C, Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007;46:531-8
   PubMed Web of Science ®Google Scholar
• Guo JJ, Li QL, Shi XF, Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naive patient. Antiviral Res 2009;81:180-3
   PubMed Web of Science ®Google Scholar
• Baldick CJ, Tenney DJ, Mazzucco CE, Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology 2008;47:1473-82
   PubMed Web of Science ®Google Scholar
• Kurashige N, Ohkawa K, Hiramatsu N, Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance. J Gastroenterol 2009;44(8):864-70
   PubMed Web of Science ®Google Scholar
• Reijnders JG, Pas SD, Schutten M, Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol 2009;50:674-83
   PubMed Web of Science ®Google Scholar
• Lai CL, Leung N, Teo EK, A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-36
   PubMed Web of Science ®Google Scholar
• Lai CL, Gane E, Liaw YF, Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88
   PubMed Web of Science ®Google Scholar
• Liaw YF, Gane E, Leung N, 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-95
   PubMed Web of Science ®Google Scholar
• Seifer M, Patty A, Serra I, Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. Antiviral Res 2009;81:147-55
   PubMed Web of Science ®Google Scholar
• van Bommel F, Zollner B, Sarrazin C, Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006;44:318-25
   PubMed Web of Science ®Google Scholar
• van der Eijk AA, Hansen BE, Niesters HG, Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. J Viral Hepat 2005;12:364-72
   PubMed Web of Science ®Google Scholar
• Marcellin P, Heathcote EJ, Buti M, Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-55
   PubMed Web of Science ®Google Scholar
• Marcellin P, Buti M, Krastev Z, Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (Study 102), preliminary analysis [abstract]. Hepatology 2008;48:370A
   Web of Science ®Google Scholar
• van Bommel F, deMan R, Reijnders J, Effectiveness of tenofovir DF (TDF) monotherapy in patients with prior experience to nucleoside/nucleotide analogues by different pattern of pre-existing mutations. J Hepatol 2009;50:S337-8
   Web of Science ®Google Scholar
• Amini-Bavil-Olyaee S, Herbers U, Sheldon J, The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 2009;49:1158-65
   PubMed Web of Science ®Google Scholar
• Gitman MD, Hirschwerk D, Baskin CH, Singhal PC. Tenofovir-induced kidney injury. Expert Opin Drug Saf 2007;6:155-64
   PubMed Web of Science ®Google Scholar
• Tan LK, Gilleece Y, Mandalia S, Reduced glomerular filtration rate but sustained virologic response in HIV/hepatitis B co-infected individuals on long-term tenofovir. J Viral Hepat 2009;16:471-8
   PubMed Web of Science ®Google Scholar
• van Bommel F, deMan R, Ferenci P, Evaluation of safety and tolerability Of Tenofovir DF (TDF) long term monotherapy in nucleos(t)ide analogue experienced patients with HBV monoinfection. J Hepatol 2009;50:S338
   Web of Science ®Google Scholar
• Kwon HC, Cheong JY, Cho SW, Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy. J Gastroenterol Hepatol 2009;24:49-54
   PubMed Web of Science ®Google Scholar
• Ijaz S, Arnold C, Dervisevic S, Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. J Med Virol 2008;80:1160-70
   PubMed Web of Science ®Google Scholar
• Pellicelli AM, Barbaro G, Francavilla R, Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. Clin Ther 2008;30:317-23
   PubMed Web of Science ®Google Scholar
• Sherman M, Yurdaydin C, Simsek H, Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008;48:99-108
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Suzuki F, Kawamura Y, Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance? J Gastroenterol Hepatol 2009;24:429-35
   PubMed Web of Science ®Google Scholar
• Yim HJ, Hussain M, Liu Y, Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006;44:703-12
   PubMed Web of Science ®Google Scholar
• Lampertico P, Vigano M, Manenti E, Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005;42:1414-9
   PubMed Web of Science ®Google Scholar
• Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007;45:307-13
   PubMed Web of Science ®Google Scholar
• Yatsuji H, Suzuki F, Sezaki H, Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008;48:923-31
   PubMed Web of Science ®Google Scholar
• Lampertico P, Vigano M, Manenti E, Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007;133:1445-51
   PubMed Web of Science ®Google Scholar
• Yeon JE, Yoo W, Hong SP, Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir. dipivoxil Gut 2006;55:1488-95
   PubMed Web of Science ®Google Scholar
• Chen CH, Wang JH, Lee CM, Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil. Antivir Ther 2006;11:771-8
   PubMed Web of Science ®Google Scholar
• Karatayli E, Karayalcin S, Karaaslan H, A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther 2007;12:761-8
   PubMed Web of Science ®Google Scholar
• Hui CK, Zhang HY, Bowden S, 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 2008;48:714-20
   PubMed Web of Science ®Google Scholar
• Sung JJ, Lai JY, Zeuzem S, Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008;48:728-35
   PubMed Web of Science ®Google Scholar
• Marcellin P, Chang TT, Lim SG, Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008;48:750-8
   PubMed Web of Science ®Google Scholar
• Vigano M, Lampertico P, Iavarone M, High risk of renal impairment during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B. J Hepatol 2009;50:S338-9
   Web of Science ®Google Scholar
• Yuen MF, Sablon E, Libbrecht E, Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment. Antivir Ther 2006;11:779-86
   PubMed Web of Science ®Google Scholar
• Santos SA, Uriel AJ, Park JS, Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen. Eur J Gastroenterol Hepatol 2006;18:1247-53
   PubMed Web of Science ®Google Scholar
• van Bommel F, de Man RA, Stein K, A multicenter analysis of antiviral response after one year of tenofovir mono-therapy in HBV-monoinfected patients with prior nucleos(t)ide analog experience [abstract]. J Hepatol 2008;48:S32
   Web of Science ®Google Scholar
• Berg T, Moller B, Trinh H, Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF for treatment of chronic hepatitis B (CHB) in subjects with persistent viral replication receiving adefovir dipivoxil (ADV) [abstract]. J Hepatol 2008;48:S34
   Web of Science ®Google Scholar
• Lutgehetmann M, Schollmeyer J, Volz T, Rescue therapy with combination of entecavir and tenofovir in patients with chronic HBV, advanced fibrosis and multiple previous treatment failures is safe and highly efficient [abstract]. J Hepatol 2009;50:S335
   Web of Science ®Google Scholar
• Marcellin P, Piratvisuth T, Brunetto M, Increasing rates of HBsAg clearance and seroconversion in patients with HBeAg-negative disease treated with peginterferon alfa-2a ± lamivudine: results of 5-year post-treatment follow up [abstract]. J Hepatol 2009;50:S336
   Google Scholar
• Wursthorn K, Lutgehetmann M, Dandri M, Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675-84
   PubMed Web of Science ®Google Scholar
• Ingiliz P, Valantin MA, Thibault V, Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. Antivir Ther 2008;13:895-900
   PubMed Web of Science ®Google Scholar
• Sarin SK, Sood A, Kumar M, Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007;102:96-104
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Risk of peripheral neuropathy with Sebivo (telbivudine). [Public Statement] 2008;EMEA/60439
   Google Scholar
• Zhang XS, Jin R, Zhang SB, Tao ML. Clinical features of adverse reactions associated with telbivudine. World J Gastroenterol 2008;14:3549-53
   PubMed Web of Science ®Google Scholar
• Wong DK, Yuen MF, Ngai VW, One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 2006;11:909-16
   PubMed Web of Science ®Google Scholar
• Mason WS, Xu C, Low HC, The amount of hepatocyte turnover that occurred during resolution of transient hepadnavirus infections was lower when virus replication was inhibited with entecavir. J Virol 2009;83:1778-89
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sevastianos V, Rapti I. Outcome of HBeAg-negative Chronic Hepatitis B (CHB) 5 years after discontinuation of long term Adefovir Dipivoxil (ADV) treatment [abstract]. J Hepatol 2009;50:S9-10
   Web of Science ®Google Scholar
• Korba BE, Montero AB, Farrar K, Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 2008;77:56-63
   PubMed Web of Science ®Google Scholar
• Elazar M, Liu M, McKenna S, Nitazoxanide (NTZ) is an inducer of eIF2a and PKR phosphorylation [abstract]. Hepatology 2008;48:1151A
   Web of Science ®Google Scholar
• Rossignol JF, Keeffe EB. Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C. Future Microbiol 2008;3:539-45
   PubMed Web of Science ®Google Scholar